Prognosis
Advisers See No Data Favoring Trump-Touted Plasma Therapy
- Convalescent plasma doesn’t improve covid-19 survival
- Therapy shouldn’t be considered standard of care, advisers say
This article is for subscribers only.
A panel of experts convened by the National Institutes of Health undercut an emergency authorization issued just days ago by U.S. regulators, saying there’s not enough evidence to recommend use of convalescent plasma for hospitalized coronavirus patients.
In an escalation of a dispute between federal agencies, the NIH advisers said an analysis of a study showed “no difference in 7-day survival overall” among those who received plasma containing high amounts of antibodies.